Browsing by Author "Verdejo H.E."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- ItemMitochondrial function, dynamics and quality control in the pathophysiology of HFpEF(Elsevier B.V., 2021) del Campo A.; Perez G.; Castro P.F.; Verdejo H.E.; Parra V.; Parra V.; Parra V.; Castro P.F.; Parra V.; Verdejo H.E.© 2021 Elsevier B.V.Heart failure (HF) is one of the leading causes of hospitalization for the adult population and a major cause of mortality worldwide. The HF syndrome is characterized by the heart's inability to supply the cardiac output required to meet the body's metabolic requirements or only at the expense of elevated filling pressures. HF without overt impairment of left ventricular ejection fraction (LVEF) was initially labeled as “diastolic HF” until recognizing the coexistence of both systolic and diastolic abnormalities in most cases. Acknowledging these findings, the preferred nomenclature is HF with preserved EF (HFpEF). This syndrome primarily affects the elderly population and is associated with a heterogeneous overlapping of comorbidities that makes its diagnosis challenging. Despite extensive research, there is still no evidence-based therapy for HFpEF, reinforcing the need for a thorough understanding of the pathophysiology underlying its onset and progression. The role of mitochondrial dysfunction in developing the pathophysiological changes that accompany HFpEF onset and progression (low-grade systemic inflammation, oxidative stress, endothelial dysfunction, and myocardial remodeling) has just begun to be acknowledged. This review summarizes our current understanding of the participation of the mitochondrial network in the pathogenesis of HFpEF, with particular emphasis on the signaling pathways involved, which may provide future therapeutic targets.
- ItemNovel molecular insights and public omics data in pulmonary hypertension(Elsevier B.V., 2021) Lopez-Crisosto C.; Arias-Carrasco R.; Maracaja-Coutinho V.; Lavandero S.; Lopez-Crisosto C.; Sepulveda P.; Verdejo H.E.; Castro P.F.; Sepulveda P.; Verdejo H.E.; Castro P.F.; Garrido-Olivares L.; Lavandero S.© 2021 Elsevier B.V.Pulmonary hypertension is a rare disease with high morbidity and mortality which mainly affects women of reproductive age. Despite recent advances in understanding the pathogenesis of pulmonary hypertension, the high heterogeneity in the presentation of the disease among different patients makes it difficult to make an accurate diagnosis and to apply this knowledge to effective treatments. Therefore, new studies are required to focus on translational and personalized medicine to overcome the lack of specificity and efficacy of current management. Here, we review the majority of public databases storing ‘omics’ data of pulmonary hypertension studies, from animal models to human patients. Moreover, we review some of the new molecular mechanisms involved in the pathogenesis of pulmonary hypertension, including non-coding RNAs and the application of ‘omics’ data to understand this pathology, hoping that these new approaches will provide insights to guide the way to personalized diagnosis and treatment.